Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Scott, Bart L  [Clear All Filters]
Journal Article
Scott BL. Allogeneic stem cell transplantation for high-risk acute leukemia and maintenance therapy: no time to waste. Blood Adv. 2020;4(13):3200-3204.
de Lima M, Oran B, Champlin RE, Papadopoulos EB, Giralt SA, Scott BL, William BM, Hetzer J, Laille E, Hubbell B, et al. CC-486 Maintenance After Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2018.
Oran B, Ahn KWoo, Fretham C, Beitinjaneh A, Bashey A, Pawarode A, Wirk B, Scott BL, Savani BN, Bredeson C, et al. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improves Transplant Outcomes in Older MDS Patients. Transplant Cell Ther. 2021.
Gupta V, Kennedy JA, Capo-Chichi J-M, Kim S, Hu Z-H, Alyea EP, Popat UR, Sobecks RM, Scott BL, Gerds AT, et al. Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase. Blood Adv. 2020;4(21):5562-5573.
Nazha A, Hu Z-H, Wang T, R Lindsley C, Abdel-Azim H, Aljurf M, Bacher U, Bashey A, Cahn J-Y, Cerny J, et al. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Myelodysplastic Syndromes Patients. Biol Blood Marrow Transplant. 2020.
Gowin K, Ballen K, Ahn KWoo, Hu Z-H, Ali H, Arcasoy MO, Devlin R, Coakley M, Gerds AT, Green M, et al. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020;4(9):1965-1973.